Delaware Court Consolidates, Postpones Trial In Adderall XR Patent Challenge

Law360, New York (April 15, 2005, 12:00 AM EDT) -- A Delaware federal court has postponed the trial in Impax Laboratories, Inc.’s patent challenge against Shire Pharmaceuticals Group’s best-selling attention-deficit-disorder treatment Adderall XR until February 2006.

Shire has two pending suits against Impax based on the generics maker’s plans to make 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg generic versions of Adderall XR.

Impax sent Shire two separate notices that it would be challenging the validity of the main ingredients in the drug, prompting two separate lawsuits for different dosages....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.